Wikipedia

Galiximab

Galiximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD80
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
(verify)

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References

  1. ^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
  2. ^ WHO Drug Information

External links


This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. The text was not checked or edited by anyone on our staff. Although the vast majority of Wikipedia® encyclopedia articles provide accurate and timely information, please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.